Selecta Biosciences selectabio.com


Public lists: Pharma Startups (4733)

Selecta Biosciences is a biopharmaceutical company developing a new class of targeted vaccines that induces an antigen-specific immune activation or antigen-specific immune tolerance for therapeutic and prophylactic applications. Selecta's Synthetic Vaccine Particle (SVP) platform creates a new paradigm in vaccine development, enabling completely new therapeutic applications while offering the potential of improved efficacy and safety profiles. Selecta's fully synthetic engineering of novel vacc...Show all

Selecta Biosciences is a biopharmaceutical company developing a new class of targeted vaccines that induces an antigen-specific immune activation or antigen-specific immune tolerance for therapeutic and prophylactic applications. Selecta's Synthetic ...Show all

Company (IPO / Went public)

Phone: 617-923-1400

Fax: 617-924-3454

480 Arsenal St.
Building One
Watertown, 02472
Massachusetts, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Selecta Biosciences $204.1M Jun 22, 2016
Peptimmune $78.7M Mar 24, 2011
Panacos Pharmaceuticals $48.3M Oct 18, 2007
See all 14 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Selecta Biosciences Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 17 investors

Competitors

Company Status Description Investors
See all 14 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Immunomodulatory agent-polymeric compounds Mar 13, 2015 Feb 06, 2018 Patent
Dose selection of adjuvanted synthetic nanocarriers May 20, 2015 Sep 19, 2017 Patent
Tolerogenic synthetic nanocarriers to reduce immune responses to therapeutic proteins Apr 27, 2012 Mar 29, 2016 Patent
Tolerogenic synthetic nanocarriers to reduce cytotoxic t lymphocyte responses Apr 27, 2012 Mar 22, 2016 Patent
Tolerogenic synthetic nanocarriers for allergy therapy Apr 27, 2012 Mar 22, 2016 Patent
See all 46 patents